Otsuka Korea to launch novel antipsychotic agent "Abilify" in early next year

Otsuka Korea said it is planning to launch Abilify (aripiprazole), a new antipsychotic agent called a dopamine system stabilizer (DSS) that has a unique mechanism of action, in Korea during the early next years after the obtainment of its import license from the Korea Food and Drug Administration. In the US and European markets, Otsuka Pharm and Bristol-Myers Squibb have engaged in their co-mar...